Last Updated: November 16, 2026

Details for Patent: 8,993,549

« Back to Dashboard


Summary for Patent: 8,993,549
Title:Natural combination hormone replacement formulations and therapies
Abstract:Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Inventor(s):Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Assignee: TherapeuticsMD Inc
Application Number:US14/475,864
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,993,549
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

US Patent 8,993,549: Estradiol-Progesterone Formulation Scope, Exclusivity and Patent Landscape

US Patent 8,993,549 protects oral pharmaceutical compositions that combine solubilized estradiol with suspended progesterone in a lipid-based solubilizing system containing C6-C12 fatty-acid mono- or diglycerides. The claims are formulation claims, not claims to estradiol, progesterone, hormone replacement therapy generally, or a particular clinical indication.

The patent’s commercial relevance is its apparent coverage of the Bijuva-type softgel formulation, including estradiol/progesterone strengths corresponding to 0.5 mg/100 mg and 1 mg/100 mg products. The strongest infringement risk arises where a competing product uses the same mixed physical state, lipid excipient class, and dosage-form architecture.

What does US Patent 8,993,549 protect?

The patent protects a composition with four central technical limitations:

  1. Estradiol is solubilized.
  2. Progesterone is suspended, although some progesterone may also be partially solubilized.
  3. Both hormones are present in the same solubilizing agent and are uniformly dispersed.
  4. At least approximately 90% of the estradiol is solubilized in an agent containing a C6-C12 fatty-acid mono- or diglyceride.

The claims therefore target a mixed formulation in which estradiol is substantially dissolved while progesterone remains at least partly suspended. That distinction separates the invention from a fully solubilized dual-hormone formulation and from a simple physical mixture of two finished drug substances.

The patent is formulation-specific. A product may contain the same active ingredients and dosage strengths yet avoid literal infringement if it does not satisfy the specified solubilization, suspension, dispersion, or excipient limitations.

How are the independent claims structured?

Claim Core solubilizing-agent limitation Principal scope
1 Monoglyceride, diglyceride, or combination containing a C6-C12 fatty-acid ester Broadest independent claim
7 Monoglyceride containing a C6-C12 fatty-acid ester Monoglyceride species
13 Diglyceride containing a C6-C12 fatty-acid ester Diglyceride species

Claims 1, 7 and 13 are composition claims. They do not require a method of treatment, administration step, pharmacokinetic result, or clinical outcome.

Claim 1 is structurally the broadest. It covers:

  • a monoglyceride;
  • a diglyceride; or
  • a combination of mono- and diglycerides,

provided the relevant agent contains an ester of a C6-C12 fatty acid.

Claim 7 narrows the composition to a monoglyceride. Claim 13 narrows it to a diglyceride. The three independent claims create overlapping protection and reduce the impact of a design-around that changes the glyceride category.

What do the dependent claims add?

Claims Limitation Commercial significance
2, 8, 14 Partially solubilized progesterone Covers a formulation in which progesterone exists in both suspended and dissolved states
3, 9, 15 Gelatin capsule Targets softgel or other gelatin-capsule presentations
4, 10, 16 At least 0.125 mg estradiol and at least 25 mg progesterone Captures commercially relevant hormone strengths
5, 11, 17 Specific progesterone-to-estradiol ratios Covers 24:1, 25:1, 96:1, 100:1, 192:1 and 200:1 ratios
6, 12, 18 Estradiol does not precipitate for at least 14 days Adds a stability or physical-performance limitation

The dosage-strength claims are broad at their lower thresholds. They are not limited to the marketed 0.5 mg/100 mg and 1 mg/100 mg strengths. The ratio claims are more commercially focused. The 100:1 and 200:1 ratios correspond to the principal Bijuva strengths.

The 14-day nonprecipitation limitation may be important in litigation because it introduces a testable product-performance requirement. A challenger may dispute the assay method, storage conditions, sampling protocol, or meaning of “does not precipitate.” A patent owner would likely rely on formulation testing and stability data to establish compliance.

What formulations are protected by US 8,993,549?

The claim language covers a formulation in which the lipid vehicle performs different functions for the two hormones:

  • estradiol is substantially solubilized;
  • progesterone is suspended or partly suspended;
  • both are uniformly distributed through the vehicle;
  • the vehicle contains a medium-chain fatty-acid glyceride.

The C6-C12 limitation is directed to medium-chain fatty-acid chemistry. Potentially relevant excipient classes include glycerides derived from caproic, caprylic, capric or lauric acid, subject to the precise chemical identity and formulation concentration.

The claims do not expressly require:

  • a specific trade-name excipient;
  • peanut oil;
  • medium-chain triglyceride;
  • a particular capsule shell;
  • a particular dissolution profile;
  • a specific bioavailability result;
  • micronized estradiol or progesterone;
  • a particular manufacturing process.

A formulation using a triglyceride rather than a mono- or diglyceride may present a design-around opportunity, but the analysis depends on the actual composition, impurities, excipient characterization and any applicable doctrine-of-equivalents theory.

How strong is the patent estate for Bijuva-type products?

The patent is strongest against a copycat that reproduces all of the following:

  • oral gelatin softgel delivery;
  • estradiol and progesterone in one lipid vehicle;
  • at least 90% estradiol solubilization;
  • progesterone suspension;
  • uniform dispersion;
  • C6-C12 mono- or diglyceride excipient;
  • 0.5 mg/100 mg or 1 mg/100 mg dosing;
  • approximately 100:1 or 200:1 hormone ratio.

The estate is weaker against a product that changes the physical formulation architecture. Potential alternatives include:

  • fully solubilizing progesterone;
  • using a non-glyceride solubilizer;
  • using a triglyceride-only vehicle;
  • separating the hormones into different dosage units;
  • using a tablet, liquid, implant or transdermal system;
  • using a formulation in which less than 90% of estradiol is solubilized;
  • demonstrating precipitation before or during the claimed 14-day period.

The patent’s protection is therefore commercially meaningful but not technology-wide. It does not prevent all generic estradiol/progesterone products. It primarily creates a barrier around a specific oral softgel formulation.

When does US Patent 8,993,549 lose exclusivity?

The patent has a nominal 20-year term measured from its earliest effective nonprovisional priority date. Public patent records associate the family with a March 2009 priority date, producing a nominal expiration date in March 2029, subject to patent-term adjustment, terminal disclaimers, fee status and any applicable patent-term extension.[1]

The patent does not receive the five-year restoration available to a new chemical entity because estradiol and progesterone were previously known active ingredients. Any regulatory exclusivity for an approved product is separate from the patent term.

Exclusivity category Relevance
Patent term Expected to run into 2029 on the ordinary 20-year calculation
New chemical entity exclusivity Not applicable to known estradiol and progesterone active ingredients
Three-year clinical-investigation exclusivity Potentially relevant to the approved combination and supporting clinical investigations
Pediatric exclusivity Applies only if separately granted by FDA
Orphan exclusivity Not the ordinary basis for Bijuva protection
Patent-term extension Requires an FDA-regulated product and statutory eligibility; the record must be checked separately

FDA approved Bijuva under NDA 210731 in 2018 as an oral combination of estradiol and progesterone for moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.[2] Regulatory exclusivity and Orange Book listing must be analyzed separately from the patent’s expiration date.

What is the Orange Book status of US 8,993,549?

US Patent 8,993,549 has been associated with the Bijuva product and its formulation protection in FDA patent-listing materials. The Orange Book identifies patents submitted by an NDA holder as covering the drug substance, drug product or method of use. A formulation patent of this type is generally evaluated as a drug-product patent rather than a drug-substance patent.[3]

The commercial consequences are:

  • an ANDA applicant must address the listed patent;
  • the applicant may certify that the patent has expired, will expire, is not infringed, or is invalid;
  • a Paragraph IV certification can trigger patent litigation;
  • a timely infringement action can impose a 30-month stay on approval, subject to statutory exceptions and FDA action.

Orange Book listings do not establish validity. They identify patents that FDA has accepted for listing based on the NDA holder’s submission and FDA’s administrative review.

Are there Paragraph IV challenges to Bijuva or this patent?

A Paragraph IV challenge would require an ANDA applicant to assert that US 8,993,549 is invalid, unenforceable or not infringed. The most credible challenge theories would focus on:

Lack of novelty or obviousness

Earlier hormone formulations may disclose estradiol, progesterone and lipid excipients individually. The challenger would need to show that the claimed combination, including the 90% estradiol-solubilization threshold and suspended progesterone architecture, was disclosed or would have been obvious.

Indefiniteness

Potential disputes could involve:

  • “uniformly dispersed”;
  • “effective amount”;
  • “partially solubilized”;
  • “does not precipitate”;
  • the testing conditions for the 14-day stability limitation.

The claims contain functional and qualitative language, but that language is not automatically indefinite. The specification, examples and analytical methods would determine whether a skilled formulator could apply the limitations with reasonable certainty.

Written description and enablement

A challenger could argue that the claims cover an undue range of C6-C12 mono- and diglyceride systems or dosage combinations not adequately supported by the specification. The patent owner would rely on formulation examples, stability data and the ordinary skill of pharmaceutical scientists.

Noninfringement

Noninfringement is likely to be the most commercially practical route. A generic manufacturer could alter the lipid vehicle, hormone physical state, capsule design or dosage-unit structure rather than reproduce every limitation.

The existence and status of any individual Paragraph IV notice letter, district-court complaint or settlement must be confirmed through FDA ANDA records and federal court filings. The patent claims alone do not establish that a Paragraph IV dispute has occurred.

What patent litigation affects US 8,993,549?

The patent should be reviewed in three litigation layers:

  1. Direct infringement litigation against an ANDA applicant.
  2. Declaratory-judgment litigation brought by a generic applicant.
  3. Patent validity or post-grant proceedings before the USPTO.

For this patent, the key litigation evidence would include:

  • the asserted claims;
  • the ANDA formulation and excipient composition;
  • the applicant’s Paragraph IV notice;
  • the filing date of the infringement complaint;
  • claim-construction rulings;
  • expert testing of solubilization and precipitation;
  • settlement terms and any permitted launch date.

A generic formulation may be difficult to evaluate from the public label alone. The composition and manufacturing information in an ANDA is not fully public. That limits the ability to determine infringement before litigation or an authorized settlement.

Which companies are challenging the Bijuva patent estate?

Bijuva’s competitive risk is primarily generic, not biosimilar. Estradiol and progesterone are small-molecule active ingredients, so a biosimilar pathway under the Public Health Service Act is not applicable. A competitor would ordinarily use an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

Potential entrants include manufacturers with experience in:

  • hormone replacement therapy;
  • softgel manufacturing;
  • lipid-based oral delivery;
  • controlled-temperature suspension processing;
  • ANDA products with formulation patents listed in the Orange Book.

The absence of an identified challenger in the supplied record does not establish that no Paragraph IV notice exists. FDA Orange Book updates and federal docket records control the current litigation picture.

How does US 8,993,549 compare with competing patent strategies?

Strategy Protection target Design-around difficulty
US 8,993,549 formulation claims Solubilized estradiol plus suspended progesterone in mono-/diglyceride vehicle Moderate
Drug-substance patent Estradiol or progesterone molecule Very high if valid, but generally unavailable for old molecules
Method-of-use patent Menopausal symptoms or hormone replacement treatment Moderate to low
Dosage-regimen patent Specific dose, schedule or patient population Variable
Manufacturing patent Mixing, heating, filling or encapsulation process Moderate
Delivery-system patent Softgel, lipid vehicle or dissolution performance Moderate
Combination-product patent Specific estradiol/progesterone ratio and strengths Moderate

US 8,993,549 has greater value than a narrow dosage claim because it ties together composition, physical state and excipient chemistry. Its value is lower than a valid compound patent because a competitor can potentially design around the formulation while retaining the same active ingredients.

What generic launch scenarios exist?

Launch after patent expiration

A generic may launch after expiration if FDA requirements are satisfied and no other listed patent or exclusivity blocks approval. The expected ordinary patent endpoint is in 2029, subject to the official patent record.

Paragraph IV launch

An ANDA applicant may launch after a favorable judgment, settlement authorization, or expiration of the relevant stay. The applicant could pursue a formulation that avoids the mono- or diglyceride limitations or the claimed physical-state requirements.

At-risk launch

An applicant may launch before final resolution, exposing itself to damages and injunctive relief if the patent is found valid, enforceable and infringed. This is less attractive where the formulation closely tracks the patented product.

Non-infringing formulation launch

A competitor may seek approval for a product with different excipient chemistry or separate dosage units. This route reduces patent risk but may increase development, bioequivalence and commercial-substitutability risk.

What revenue exposure does the patent create?

The patent has its highest revenue relevance for products that depend on the oral combined estradiol/progesterone softgel format. It does not block:

  • estradiol-only products;
  • progesterone-only products;
  • transdermal estrogen;
  • vaginal estrogen;
  • separate estrogen and progesterone prescriptions;
  • non-infringing oral combinations.

Revenue exposure therefore depends on how much of the product’s sales derive from the protected formulation rather than from the active ingredients generally. Generic entry could reduce price and market share materially if the competing product is therapeutically substitutable and receives AB-rated approval.

The patent estate may delay direct substitution even after regulatory approval if additional Orange Book patents remain listed. A full launch analysis must therefore assess the entire Bijuva patent family, not US 8,993,549 in isolation.

Key Takeaways

  • US 8,993,549 is a formulation patent for estradiol/progesterone oral compositions.
  • The core requirement is at least 90% solubilized estradiol with suspended progesterone in a C6-C12 mono- or diglyceride vehicle.
  • Claims 1, 7 and 13 create overlapping protection for mixed, monoglyceride and diglyceride systems.
  • The 100:1 and 200:1 ratio claims are particularly relevant to 0.5 mg/100 mg and 1 mg/100 mg products.
  • Gelatin-capsule claims target the commercial softgel presentation but do not independently define the entire invention.
  • The patent’s nominal term extends to approximately March 2029, subject to official patent-term adjustments and related legal events.
  • Generic competition would likely proceed through an ANDA, not a biosimilar application.
  • The most credible design-arounds alter the lipid excipient, hormone physical state, dosage-unit structure or delivery system.
  • Patent validity and infringement depend heavily on formulation testing, excipient characterization and the interpretation of “uniformly dispersed” and “does not precipitate.”
  • The commercial risk cannot be assessed from this patent alone; the complete Orange Book listing and related patent family must be considered.

FAQs

Is US Patent 8,993,549 a drug patent or a formulation patent?

It is a formulation patent. It does not claim estradiol or progesterone as chemical entities. It claims a specific pharmaceutical composition and its physical and excipient characteristics.

Does the patent cover every estradiol and progesterone combination?

No. A competing product must satisfy the claimed solubilization, suspension, dispersion and glyceride limitations, or a court must find infringement under the doctrine of equivalents.

Can a generic avoid the patent by using a triglyceride?

Possibly. The claims expressly identify monoglycerides and diglycerides, while a triglyceride-only formulation may fall outside the literal claim language. The complete formulation and any equivalent-function analysis remain material.

Does a gelatin capsule alone infringe US 8,993,549?

No. The gelatin-capsule limitation appears only in dependent claims. The composition must also satisfy the independent claim requirements.

Is a biosimilar required to compete with Bijuva?

No. Estradiol and progesterone are small-molecule drugs. A competing oral combination would generally use the ANDA pathway rather than the biosimilar pathway.

References

  1. United States Patent and Trademark Office. (2015). U.S. Patent No. 8,993,549, pharmaceutical compositions comprising estradiol and progesterone.
  2. U.S. Food and Drug Administration. (2018). Bijuva prescribing information. TherapeuticsMD, Inc.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,993,549

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-002 Dec 28, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,993,549

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2782584 ⤷  Start Trial 301153 Netherlands ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 2021C/558 Belgium ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 122021000080 Germany ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial LUC00245 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.